Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
34.28
+0.39 (1.15%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.
Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Harmony Biosciences Holdings, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Aug 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 246 |
| CEO | Jeffrey Dayno |
Contact Details
Address: 630 West Germantown Pike, Suite 215 Plymouth Meeting, Pennsylvania 19462 United States | |
| Phone | 484 539 9800 |
| Website | harmonybiosciences.com |
Stock Details
| Ticker Symbol | HRMY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $24.00 |
| CIK Code | 0001802665 |
| CUSIP Number | 413197104 |
| ISIN Number | US4131971040 |
| Employer ID | 82-2279923 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey M. Dayno M.D. | President, Chief Executive Officer and Director |
| Jeffrey S. Aronin | Founder and Non-Executive Chairman |
| Sandip S. Kapadia CPA, M.B.A. | Executive Vice President, Chief Administrative Officer and Chief Financial Officer |
| Dr. Kumar Budur M.D., M.S. | Executive Vice President and Chief Medical and Scientific Officer |
| Jeffrey Dierks M.B.A. | Executive Vice President and Chief Commercial Officer |
| Andrew Serafin J.D., M.B.A. | Executive Vice President and Chief Strategy Officer |
| David Bradshaw | Head of Technical Operations |
| Brennan Doyle | Vice President and Head of Investor Relations |
| Christian Ulrich J.D. | General Counsel and Corporate Secretary |
| Tricia Glover | Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 1, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 424B7 | Filing |
| Oct 29, 2024 | 424B7 | Filing |
| Oct 29, 2024 | 144 | Filing |
| Oct 29, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 3, 2024 | 144 | Filing |
| Oct 1, 2024 | 144 | Filing |
| Oct 1, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 144 | Filing |